Company Overview - Inari Medical offers purpose-built solutions and differentiated devices for venous thrombectomy [9] - The company's core VTE market opportunity is $58 billion in the U S alone, with Inari penetration remaining less than 5% [9] - Inari has a robust product pipeline, launching 6 new products YTD in 2022 [9] Products and Solutions - ClotTriever system is effective on clot of all ages, with 91% complete or near complete thrombus removal for acute clots, 82% for subacute, and 84% for chronic [45] - FlowTriever is designed to extract large volumes of clot, offering a lytic-free approach [58] - FlowTriever aspiration flow rate is 8x greater than 12F catheter [62] Clinical Evidence and Studies - ClotTriever studies show 92% complete or near complete thrombus removal, 99% single session rate, 1% received lytics, 0 0% major bleeding, and 0 0% acute kidney injury [77, 78, 79] - FlowTriever studies show 1 6% acute mortality, 0 0% device related mortality, 7 0 mmHg average mPAP decrease, 1 0% major bleeding, and 0 9-day average ICU stay [81, 82] - PEERLESS is an RCT of FlowTriever vs catheter-directed thrombolytics in pulmonary embolism, enrolling up to 700 patients [83] Financial Performance - The company's Q3 2022 revenue was $96 2 million, with 4% sequential growth from Q2 2022 and 32% growth YoY from Q3 2021 [93] - Q3 YTD 2022 revenue mix was 32% CT and 68% FT [93] - Gross margin was 88 6% in Q3 2022 [93]

Inari Medical, Inc. (NASDAQ:NARI) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Caroline Corner ??? Investor Relations Bill Hoffman ??? President and Chief Executive Officer Drew Hykes ??? Chief Operating Officer Mitch Hill ??? Chief Financial Officer Tom Tu ??? Chief Medical Officer Conference Call Participants Travis Steed ??? Bank of America Cecilia Furlong ??? Morgan Stanley Larry Biegelsen ??? Wells Fargo Marie Thibault ??? BTIG Bill Plovanic ??? Canaccord Genuity Ad ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to ___________ Commission File Number: 001-39293 Inari Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 45-2902923 ( ...

Welcome Remarks Kevin Strange, VP Strategy and Business Development Sandy | Boynton Beach, FL Inari Investor Day Agenda | --- | --- | |-------------------------|-----------------------------------------------------------------------| | Time | Session | | 7:30 – 8:00 AM | Registration and Breakfast Bar | | 7:55 – 8:00 AM | Welcome Remarks | | 8:00 – 8:45 AM | Site Tour and VTE Tech Demos | | 8:45 – 9:00 AM Break | | | 9:00 – 11:30 AM | Management Presentation | | 11:30AM – 12:00 PM | Informal lunch, New Prod ...

Inari Medical, Inc. (NASDAQ:NARI) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Caroline Corner - IR Bill Hoffman - President and CEO Mitch Hill - CFO Drew Hykes - COO Tom Tu - CMO Conference Call Participants Cecilia Furlong - Morgan Stanley Larry Biegelsen - Wells Fargo Marie Thibault - BTIG William Plovanic - Canaccord Genuity Adam Maeder - Piper Operator Good day, and thank you for standing by. Welcome to the Inari Medical Inc. Second Quarter Earnings Conference Call. [ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to ___________ Commission File Number: 001-39293 Inari Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 45-2902923 ( Stat ...

Investor Presentation NASDAQ: NARI May 4, 2022 This presentation (together with any other statements or information that we may make in connection therewith) may contain are forward-looking statements. All statements other than statements of historical fact could be deemed forward-looking, including any estimates of fourth quarter revenue and total procedures, the potential impact of COVID-19 on the business, total addressable market, future results of operations, financial position, research and developmen ...

Inari Medical, Inc. (NASDAQ:NARI) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Caroline Corner - IR Bill Hoffman - CEO Mitch Hill - CFO Drew Hykes - COO Tom Tu - CMO Conference Call Participants Travis Steed - Bank of America Cecilia Furlong - Morgan Stanley Larry Biegelsen - Wells Fargo Marie Thibault - BTIG Priya Sachdeva - SVB Leerink Operator Good day, and thank you for standing by. Welcome to the Inari Medical First Quarter 2022 Earnings Call. [Operator Instructions] Ple ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to ___________ Commission File Number: 001-39293 Inari Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 45-2902923 ( Sta ...

Inari Medical, Inc. (NASDAQ:NARI) Q4 2021 Results Conference Call February 23, 2022 4:30 PM ET Company Participants Caroline Corner - IR Bill Hoffman - President and CEO Mitch Hill - CFO Tom Tu - Chief Medical Officer Conference Call Participants Cecilia Furlong - Morgan Stanley Danielle Antalffy - SVB Leerink Marie Thibault - BTIG Operator Good day, and thank you for standing by. Welcome to the Inari???s Fourth Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. ...